Melasma melasma, autologous platelet-rich plasma, hydroquinone
Conditions
Interventions
Comparative study between topical hydroquinone 4% alone versus its combination with intradermal autologous platelet-rich plasma in the treatment of melasma: a split-face controlled trial. Participants
Experimental Procedure/Surgery,Sham Comparator Drug
PRP and topical hydroquinone cream,Hydroquinone cream alone
Sponsors
Institute of Dermatology
Eligibility
Sex/Gender
Female
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Otherwise healthy volunteers with Fitzpatrick skin type 2, 3, 4 who have melasma on both sides of cheeks, symmetrical or nearly symmetrical
Exclusion criteria
Exclusion criteria: Individuals who tend to develop keloid/acne or having active infection such as herpes, HIV, hepatitis, on oral isotretinoin or hormonal therapy within 6 months prior to this study, has a history of bleaching/whitening agents/laser therapy/botulinum toxin injection within 6 months or filler injection within 2 years prior to this study, pregnancy, lactation, smoking, bleeding tendency, facial dermatitis, skin malignancy or other skin conditions which might affect study results, on oral or topical antioxidants including vitamin C and whitening agents and those who has more than 3 hours of sun exposure per day.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy 2,4,6,8,12,16 weeks Biophysical properties of the skin, Clinical photographs | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety 2,4,6,8,12,16 weeks Patient satisfaction questionaire | — |
Countries
Thailand
Contacts
Public ContactChanisa Kiatsurayanon
Institute of Dermatology
Outcome results
None listed